In a supercooled lab setting, a tiny crystal has quietly flipped a half-century-old assumption on its head. Scientists at ...

Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an ...

We recently published a list of 10 Stocks Investors Dumped Fast. In this article, we are going to take a look at where ...

JPMorgan lowered the firm’s price target on Sarepta (SRPT) to $30 from $84 and keeps an Overweight rating on the shares. The firm made changes to ...

Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read ...

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.

Understand the cash flow statement for Sarepta Therapeutics, Inc. (SRPT), learn where the money comes from and how the company spends it.

A downtrend has been apparent in Sarepta Therapeutics (SRPT) lately. While the stock has lost 25.6% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was formed ...